Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases

NCT06328465 is registered in ClinicalTrials.gov with European Institute of Oncology as lead sponsor.

NCT NCT06328465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06328465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases
Lead sponsor
European Institute of Oncology
Phase
Not applicable
Overall status
Recruiting
Start date
November 22, 2019
Completion date
December 31, 2028
Enrollment
145 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer, invasive breast cancer, triple negative breast cancer